Quantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours.
A monoclonal antibody, RAP-5, raised against the 21,000d ras-oncogene product, p21, was used in an immunoperoxidase staining procedure to study the expression of p21 in normal children's and foetal kidneys, pre-malignant lesions and benign and malignant childhood renal tumours with good, moderate or poor prognosis. ras-p21 was expressed in both normal and foetal kidneys but its distribution in renal tumours differed markedly (p less than 0.01). A quantitative liquid competition radioimmunoassay (RIA) was used to determine ras-p21 level in tissue homogenates. The results were expressed as pg of ras-p21 per microgram protein of tissue extract. There were significant differences in the levels of ras-p21 among various renal tissue extracts (p less than 0.05). Generally it emerged that the amount of ras-p21 was greater in both malignant renal tumours and foetal kidneys compared to normal kidneys, pre-malignant lesions and benign renal tumours.
Kumar
S
S
Christie Hospital and Holt Radium Institute, Manchester, England.
Hand
P H
PH
Marsden
H B
HB
Kumar
P
P
Thor
A
A
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000032:analysis*; D002292:Carcinoma, Renal Cell / Q000235:genetics / Q000473:pathology; D002648:Child; D005333:Fetus; D011905:Genes, ras; D006801:Humans; D007124:Immunoenzyme Techniques; D007668:Kidney / Q000166:cytology / Q000196:embryology / Q000502:physiology*; D007680:Kidney Neoplasms / Q000235:genetics / Q000473:pathology*; D011230:Precancerous Conditions / Q000235:genetics / Q000473:pathology; D016283:Proto-Oncogene Proteins p21(ras) / Q000032:analysis* / Q000235:genetics; D011863:Radioimmunoassay; D012016:Reference Values; D009396:Wilms Tumor / Q000235:genetics / Q000473:pathology
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)